DNLI
Price
$12.29
Change
-$1.31 (-9.63%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
1.78B
41 days until earnings call
VRDN
Price
$12.56
Change
-$0.92 (-6.82%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
1.02B
35 days until earnings call
Ad is loading...

DNLI vs VRDN

Header iconDNLI vs VRDN Comparison
Open Charts DNLI vs VRDNBanner chart's image
Denali Therapeutics
Price$12.29
Change-$1.31 (-9.63%)
Volume$58.49K
Capitalization1.78B
Viridian Therapeutics
Price$12.56
Change-$0.92 (-6.82%)
Volume$38.83K
Capitalization1.02B
DNLI vs VRDN Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. VRDN commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and VRDN is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (DNLI: $13.60 vs. VRDN: $13.48)
Brand notoriety: DNLI and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 315% vs. VRDN: 110%
Market capitalization -- DNLI: $1.78B vs. VRDN: $1.02B
DNLI [@Biotechnology] is valued at $1.78B. VRDN’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, both DNLI and VRDN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • VRDN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than VRDN.

Price Growth

DNLI (@Biotechnology) experienced а -7.89% price change this week, while VRDN (@Biotechnology) price change was -12.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

DNLI is expected to report earnings on May 13, 2025.

VRDN is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.79B) has a higher market cap than VRDN($1.02B). VRDN YTD gains are higher at: -29.682 vs. DNLI (-33.292). VRDN has higher annual earnings (EBITDA): -266.36M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. VRDN (718M). VRDN has less debt than DNLI: VRDN (21.1M) vs DNLI (48.7M). VRDN has higher revenues than DNLI: VRDN (302K) vs DNLI (0).
DNLIVRDNDNLI / VRDN
Capitalization1.79B1.02B174%
EBITDA-492.89M-266.36M185%
Gain YTD-33.292-29.682112%
P/E RatioN/AN/A-
Revenue0302K-
Total Cash832M718M116%
Total Debt48.7M21.1M231%
FUNDAMENTALS RATINGS
DNLI vs VRDN: Fundamental Ratings
DNLI
VRDN
OUTLOOK RATING
1..100
6713
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
10092
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
9083
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRDN's Valuation (92) in the Biotechnology industry is in the same range as DNLI (94). This means that VRDN’s stock grew similarly to DNLI’s over the last 12 months.

VRDN's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as DNLI (100). This means that VRDN’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as VRDN (98). This means that DNLI’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (83) in the Biotechnology industry is in the same range as DNLI (90). This means that VRDN’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as VRDN (100). This means that DNLI’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIVRDN
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 16 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
79%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MVGNX17.090.07
+0.41%
MFS Low Volatility Global Equity R6
SLVRX32.94N/A
N/A
Columbia Select Large Cap Value R
GSATX30.09N/A
N/A
Goldman Sachs Small Cp Val Insghts A
VSPGX759.01N/A
N/A
Vanguard S&P 500 Growth Index Instl
MIGIX15.75N/A
N/A
Morgan Stanley Inst Global Insgt I

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with ARWR. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-8.02%
ARWR - DNLI
55%
Loosely correlated
-7.81%
BEAM - DNLI
54%
Loosely correlated
-12.07%
RCKT - DNLI
54%
Loosely correlated
-12.12%
CRSP - DNLI
53%
Loosely correlated
-8.00%
NTLA - DNLI
52%
Loosely correlated
-11.90%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with FATE. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-6.65%
FATE - VRDN
49%
Loosely correlated
-6.97%
DNLI - VRDN
47%
Loosely correlated
-8.02%
AURA - VRDN
46%
Loosely correlated
-7.57%
CRBU - VRDN
44%
Loosely correlated
-2.77%
TERN - VRDN
44%
Loosely correlated
-5.48%
More